6.54
price up icon1.08%   0.07
after-market After Hours: 6.52 -0.02 -0.31%
loading
Precision Biosciences Inc stock is traded at $6.54, with a volume of 237.80K. It is up +1.08% in the last 24 hours and up +63.91% over the past month. Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$6.47
Open:
$6.4
24h Volume:
237.80K
Relative Volume:
0.87
Market Cap:
$161.71M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.2624
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
-2.68%
1M Performance:
+63.91%
6M Performance:
+29.25%
1Y Performance:
+44.37%
1-Day Range:
Value
$6.40
$6.83
1-Week Range:
Value
$6.20
$6.8573
52-Week Range:
Value
$3.53
$8.82

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Name
Precision Biosciences Inc
Name
Phone
919-314-5512
Name
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Employee
68
Name
Next Earnings Date
2026-03-12
Name
Latest SEC Filings
Name
DTIL's Discussions on Twitter

Compare DTIL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
DTIL icon
DTIL
Precision Biosciences Inc
6.54 159.98M 34.26M -46.61M -62.01M -5.1806
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.74 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
756.73 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.16 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
692.83 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
147.60 31.97B 606.42M -1.28B -997.58M -6.403

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-30-24 Initiated Guggenheim Buy
Jun-17-22 Initiated BMO Capital Markets Outperform
Jun-09-22 Downgrade William Blair Outperform → Mkt Perform
Jul-27-20 Resumed BTIG Research Buy
Apr-03-20 Downgrade Goldman Buy → Neutral
Mar-05-20 Initiated Stifel Buy
Feb-25-20 Initiated William Blair Outperform
Aug-09-19 Initiated BTIG Research Buy
Jul-16-19 Initiated H.C. Wainwright Buy
Apr-22-19 Initiated Barclays Overweight
Apr-22-19 Initiated Goldman Buy
Apr-22-19 Initiated JP Morgan Overweight
Apr-22-19 Initiated Jefferies Buy
View All

Precision Biosciences Inc Stock (DTIL) Latest News

pulisher
07:32 AM

Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

07:32 AM
pulisher
12:56 PM

VIX Spike: How does Precision BioSciences Inc compare to its peersQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

12:56 PM
pulisher
Mar 25, 2026

Decliners Report: Is Rafael Holdings Inc Equity Warrant stock a good dividend stockProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

Meme Stocks: What is the PEG ratio of Precision BioSciences Inc2026 Opening Moves & Risk Managed Investment Strategies - baoquankhu1.vn

Mar 24, 2026
pulisher
Mar 24, 2026

Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday - MarketBeat

Mar 24, 2026
pulisher
Mar 23, 2026

Q1 EPS Estimate for Precision BioSciences Raised by Analyst - MarketBeat

Mar 23, 2026
pulisher
Mar 22, 2026

Is Precision BioSciences Inc stock trending bullishWeekly Loss Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 21, 2026

If You Invested $1,000 in Precision Biosciences (DTIL) - Stock Titan

Mar 21, 2026
pulisher
Mar 21, 2026

Growth Value: How does Precision BioSciences Inc compare to its peers2026 Institutional Moves & AI Driven Stock Movement Reports - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 20, 2026

Brokers Set Expectations for DTIL Q1 Earnings - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

ETFs Investing in Precision BioSciences, Inc. Stocks - TradingView

Mar 20, 2026
pulisher
Mar 20, 2026

DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill

Mar 20, 2026
pulisher
Mar 18, 2026

Portfolio Recap: Is Precision BioSciences Inc likely to announce a buybackTrade Risk Summary & High Return Stock Watch Alerts - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 18, 2026

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst CallSlideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha

Mar 18, 2026
pulisher
Mar 18, 2026

Jones Trading reiterates Precision BioSciences stock rating on DMD trial design - Investing.com Canada

Mar 18, 2026
pulisher
Mar 18, 2026

Jones Trading reiterates Precision BioSciences stock rating on DMD trial design By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 17, 2026

Precision BioSciences Announces PBGENE-DMD Investor Update and Highlights ARCUS Gene Editing Platform – March 2026 - Minichart

Mar 17, 2026
pulisher
Mar 17, 2026

Precision BioSciences Highlights PBGENE-DMD Program and Trial - TipRanks

Mar 17, 2026
pulisher
Mar 17, 2026

PBGENE-DMD gene editing strategy at Precision BioSciences (NASDAQ: DTIL) - Stock Titan

Mar 17, 2026
pulisher
Mar 16, 2026

Quarterly Risk: How volatile is Precision BioSciences Inc stockEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn

Mar 16, 2026
pulisher
Mar 15, 2026

Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN

Mar 15, 2026
pulisher
Mar 15, 2026

Precision BioSciences (DTIL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan

Mar 15, 2026
pulisher
Mar 14, 2026

Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS

Mar 14, 2026
pulisher
Mar 14, 2026

Precision BioSciences Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Australia

Mar 14, 2026
pulisher
Mar 14, 2026

Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st

Mar 13, 2026
pulisher
Mar 13, 2026

Precision BioSciences Inc buy Jefferies Financial Group Inc. - sharewise.com

Mar 13, 2026
pulisher
Mar 13, 2026

Jefferies cuts Precision BioSciences stock price target on valuation By Investing.com - Investing.com Australia

Mar 13, 2026
pulisher
Mar 13, 2026

DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 13, 2026
pulisher
Mar 13, 2026

Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com

Mar 13, 2026
pulisher
Mar 13, 2026

Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks

Mar 13, 2026
pulisher
Mar 13, 2026

Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1%Here's Why - MarketBeat

Mar 13, 2026
pulisher
Mar 12, 2026

Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - PharmiWeb.com

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - BioSpace

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and Statistics - IndexBox

Mar 12, 2026
pulisher
Mar 12, 2026

Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences (NASDAQ: DTIL) turns Q4 profit and extends cash runway to 2028 - Stock Titan

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences: Q4 Earnings Snapshot - Barchart.com

Mar 12, 2026
pulisher
Mar 12, 2026

Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Canada

Mar 12, 2026
pulisher
Mar 11, 2026

Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia

Mar 11, 2026
pulisher
Mar 11, 2026

Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com

Mar 11, 2026
pulisher
Mar 11, 2026

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - BioSpace

Mar 11, 2026

Precision Biosciences Inc Stock (DTIL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$27.35
price down icon 0.04%
$46.94
price down icon 0.19%
$53.57
price up icon 0.06%
$87.46
price down icon 1.48%
ONC ONC
$276.95
price down icon 2.29%
$147.60
price down icon 0.48%
Cap:     |  Volume (24h):